A trial in Amsterdam treating crack cocaine addiction with dexamfetamine has been temporarily suspended following intervention by the Health and Youth Care Inspectorate (IGJ), which halted production of the medication. Amsterdam was participating in research examining the use of dexamfetamine, typically prescribed for ADHD, to reduce crack cocaine dependency. The municipality reports that initial participants had already received the drug, though the total number of participants remains undisclosed. The IGJ has not disclosed the specific reasons for halting production, citing an ongoing oversight procedure regarding the manufacturing of pharmaceuticals at the involved hospital. Amsterdam officials, including council member Scholtes and Mayor Halsema, have expressed grave concerns and sent an urgent letter to the Minister of Public Health, requesting a review of the decision. According to the Amsterdam Public Health Service (GGD), between 3,000 and 9,000 people in Amsterdam are struggling with crack cocaine addiction.